eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
vol. 29
Poleć ten artykuł:
streszczenie artykułu:
Artykuł redakcyjny

Funkcja komórek beta we wczesnym stadium cukrzycy typu 1: ciągle jeszcze długa droga przed nami

Alfonso Galderisi

Yale University, Department of Pediatrics, New Haven, CT – USA
Pediatr Endocrinol Diabetes Metab 2023; 29 (1): 1-3
Data publikacji online: 2023/04/11
Pełna treść artykułu Pobierz cytowanie
Metryki PlumX:

The clinical onset of type 1 diabetes (namely stage 3 type 1 diabetes [T1D]) is preceded by a relatively prolonged pre-symptomatic phase featured by islet autoimmunity [1] with (Stage 2 T1D) or without (Stage 1 T1D) dysglycaemia. While islet autoimmunity is the hallmark of the underlying autoimmune process, very little evidence is available for the metabolic changes that accompany the loss of functional beta cell mass. Indeed, a steep decline of C-peptide – a surrogate marker of beta cell function – is measurable only ~6 months before the onset of Stage 3 T1D [2]. Disease modifier drugs have, there-fore, a very limited window of intervention because we lack of effective methods to track beta cell function over time and to identify early changes of insulin secretion that precedes dysglycaemia [3, 4] and clinically symptomatic diabetes.

Herein, we will revise current approaches to longitudinally track beta cell function over time before the onset of Stage 3 T1D, which might be suitable for monitoring the risk for diabetes progression as well as the effectiveness of disease modifier treatments.
słowa kluczowe:

cukrzyca typu 1, komórki beta, OGTT, CGM, stan przedcukrzycowy

facebook linkedin twitter
© 2023 Termedia Sp. z o.o.
Developed by Bentus.